FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis
FRI0446 Treatment with Tildrakizumab, An Anti-IL-23P19 Monoclonal Antibody, Improves Health-Related Quality of Life in Patients with Chronic Plaque Psoriasis